




PHARMACOKINETIC STUDIES OF NEW SILVER-BASED COMPLEX 
 
VLADIMIR SILNIKOV1, EVGENII PLOTNIKOV2*, VLADIMIR PLOTNIKOV
1Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, Russia, 2Tomsk Polytechnic University, Tomsk, Russia 
Email: plotnikov.e@mail.ru  
2 
Received: 21 Feb 2015 Revised and Accepted: 20 Mar 2015 
ABSTRACT 
Objective: Investigation of pharmacokinetics parameters of the new silver-based compound of general formula C6H19Ag2N4LiO6S2, called “Argosil”, 
with high antiviral activity. 
Methods: Water solution of complex administered intragastrically in the dose rate of 100 mg/kg body weight of mice BALB/c (males) aged 1.5-2.0 
mo. Blood and tissues samples analyzed by mass spectrometry. 
Results: Half-life of the drug was about 4 h at the initial stage. About 5% of the initially introduced silver detected after 24 h. Maximum drug 
concentration observed in the lung tissues.  
Conclusion: Results make the basis for further test and clinical implementation. Taken into account low toxicity and antiviral properties of this 
compound, it looks especially effective for lung infections treatment. 
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INTRODUCTION 
Since ancient times, silver has being used as anti-infective agent in 
various forms and applications. However, silver (nanoparticles, 
ionized form etc.) has significant toxic side effects, including argyria 
(deposition of insoluble silver in skin and cornea) [1]. An important 
challenge for a modern pharmacy is to create and study of new 
compounds contribute to solving the problem of infectious diseases 
and drug resistance. In this regard, it is topical to develop new silver 
compounds with high biological activity and low toxicity and the 
study of its pharmacokinetics parameters [2]. 
The purpose of this work-the study of the pharmacokinetics of the 
new silver-based compound of general formula C6H19Ag2N4LiO6S2, 
called “Argosil”. 
Previously, we have shown low toxicity and antiviral properties of 
compounds of this group [3].  
MATERIALS AND METHODS 
The object of study 
The substance “Argosil” was tested as a 1% solution in double 
distilled autoclaved water with moderate heating (37 °C). As it 
previously established, 50% of the effective antiviral dose, ED50 
equal 2.66 mg/kg. It has also been shown that the antimicrobial 
effect is achieved at doses approximately 100 times higher than the 
doses at which begins to show antiviral activity. Based on these data, 
dose of 100 mg/kg was chosen for present pharmacokinetics study. 
This dose reveal an antibacterial effect and significantly higher than 
the dose at which an antiviral effect is observed, so it covers all anti-
infection spectrum. 
Experimental animals 
Mice BALB/c (males, 1.5-2.0 mo age) were used as a model animal 
for studying pharmacokinetics parameters. Six mice were used for 
each time point. Substance was administered intragastrically in 
water solution in the dose of 100 mg/kg body weight. Spleen, 
kidney, stomach, liver, lung, muscle, skin, blood from retro orbital 
sinus was selected for histological examination. Organs and tissue, 
sampling was performed at 5 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 
16 h and 24 h after drug administration. The volume of the collected 
blood was not less than 1.0 ml. Biopsies of soft tissues (spleen, 
stomach, liver, kidneys, lungs, muscles) immediately after collection, 
preparation, removal of blood, weighed to the nearest 1 mg and 
placed in a plastic laboratory ware. Mass of tissue sample varied of 
0.1 g (minimum) to 5 g. All the samples were stored at-18 °C, 
avoiding thawing tissues. 
Sample preparation 
The tissue samples were transferred into autoclave DAP 60K volume 
of 60 ml. Eppendorf tube was washed thoroughly twice 1.0-1.5 ml of 
concentrated nitric acid, after that washings joined to the sample. 
Mineralization of samples was carried out by adding 5-10 ml of 
concentrated nitric acid in an autoclave DAP 60K with microwave 
heating using a microwave sample preparation system-speed 
wave® MWS-2 (Berghof, Germany) according to the standard 
technique. After cooling, the clear solution purified from oxides of 
nitrogen and quantitatively transferred into a glass flask of 25 ml.  
Analysis of samples 
Sample analysis was performed by mass spectrometry with 
inductively coupled plasma (ICP-MS), using the quadrupole mass 
spectrometer 7500a Agilent (Agilent Technologies, USA). 
The analysis performed according to the technical instruction 
manual of the device [1], using FullQuant mode with isotope 107Ag, 
three lines on the peak, and five replicates of measurements (fig. 1). 
Calibration curve traced by five calibration solutions prepared by 
diluting the standard solution (GSO 8204-2002). 
Reagents 
Deionized water was prepared using a water purification system 
Direct-Q 3 UV (Millipore, France) according to the technical manual. 
Resistivity of purified water was 18.2 mega-ohm (at 25 °C). 
Deionized water used to prepare working solutions, washing and 
rinsing autoclaves and volumetric glassware. The concentration of 
silver in the deionized water was less than 0.093 µg/l. Nitric acid of 
high purity. Commercially available concentrated nitric acid 
(standard sample GOST 4461-77) purified by double distillation (at 
a temperature below the boiling point) on the device Duo Pure 
(Milestone, Italy). The concentration of nitric acid in the distilled 
azeotropic mixture was 69.2%. The required solutions of nitric acid 
of high purity were prepared by diluting appropriate aliquots of 
concentrated acid with deionized water. Standard solution of silver 
for the calibration curve was prepared by diluting 0.3% HNO3 with 
appropriate aliquots of the standard sample solution of silver ions 
(standard sample GSO 8204-2002 certified), manufactured by JSC 
“Ural Plant of Chemical Reagents”. A solution of the blank sample is 
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prepared by adding aliquots of an acid sample without adding the 
sample after microwave heating; the transparent substrate 
transferred into a volumetric flask and diluted with 25 ml of 
deionized water to account for baseline concentrations. 
 
 
Fig. 1: Mass-spectrogram of “Argosil” sample 
 
Processing of measurement results 
The control program of spectrometer Chemstation [4] performed 
calibration curves and the calculation of the concentration of the 
element. Data processing performed by statistical software 
“Statgraphics, Vers.5.0” (Statistical Graphics Corp., USA). The 
accuracy of the detected intergroup differences were evaluated 
using Student t-test. Differences were significant at p ≤ 0.05. 
Experimental data were checked against the normal distribution to 
assess the possibility of using the t-test. Pairwise comparison of 
samples performed using t-test. The results recalculated into weight 
of the complex based on the fact that silver is 37.2 mass percentage 
of complex “Argosil”. Pharmacokinetic parameters were calculated 
in accordance with [5, 6]. 
RESULTS AND DISCUSSION 
Specific drug content in the tissues and organs after a single 
intragastric administration of 100 mg/kg shown in table 1. 
Distribution is uneven because of differences in blood perfusion and 
tissue properties. 
 
Table 1: The specific drug content in the mice tissues after a single administration 
Time, h Organs and tissues 
Stomach, µg/g Lungs, µg/g Liver, µg/g Spleen, µg/g Kidney, µg/g Blood, µg/g Muscle, µg/g 
0.08 374.4±9.7  0.129±0.02 1.320±0.46 0.146±0.03 3.72±0.29  0.972±0.10 3.39±0.26 
0.5 321.9±3.9  16.79±1.05  2.489±0.43 1.728±0.18 2.67±0.36  1.303±0.29 3.03±0.55 
1 257.0±4.2  19.98±2.29 2.49±0.11 4.31±0.48 1.28±0.18 2.32±0.33 6.35±0.67 
2 175.4±7.1  19.85±0.79 2.44±0.43 4.97±1.57 1.54±0.36 3.314±0.09 4.76±1.43 
4 117.6±3.5  29.85±0.79 5.086±0.40 5.104±0.74 6.67±1.72  4.093±0.72 4.10±0.59 
6 92.00±3.1 20.68±3.47  10.52±1.47  8.25±0.70 5.35±0.39  3.55±0.64 3.15±0.48 
8 67.39±3.1 17.39±2.04 14.17±1.58  14.24±1.07  7.62±0.91  2.81±0.37 4.37±0.59 
10 45.05±2.67  11.28±0.90 13.65±1.56  13.30±1.32  5.34±0.83  1.63±0.21 1.95±0.48 
16 23.40±1.04  6.24±0.73  7.99±1.20 10.07±0.93  3.80±0.68  0.68±0.05 0.83±0.38 
24 7.99±0.55  1.79±0.65  3.99±1.29 4.63±0.61 0.64±0.07 0.41±0.04 0.75±0.15 
 
Percentage of the drug found in the organs of mice at different time 
points after drug administration, shown in fig. 2. The 100% point is 
total content of the drug, revealed in all samples after 5 min of 
administration. In the initial phase, half-life of the drug was about 3 
h. After 24 h, in the body is detected approximately 5% of the 
initially introduced silver (fig. 2). After 48 h revealed about 2% of 
the total silver amount, detected in the first 5 min after its 
administration. 
Accumulation and excretion of the drug from the tissue adequately 
approximated by the equation describing the model [5]: С(t) = А1×е-
αt+А2×е-βt, 
where C (t)-the concentration of drug in the tissue at time t, µg/g; A1 
and A2-the amount of drug which is eliminated from 1 g of tissue, 
respectively, the first and second phases of the process of 
elimination, µg/g; α and β-complex parameters, which are 
proportional to a constant rate of excretion of the drug in the first 
and second stages of the process.  
Small amount of the drug (about 0.2% of the initially administered 
drug) appeared in the blood in 5 min after administration.  
 
Fig. 2: The total content of the preparation in all samples 
Plotnikov et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 6, 41-43 
43 
Fluctuations in the concentration range of 0.2-1.0% observed 
throughout the experiment. The maximum concentration (Cmax = 
4.093 g/ml) in the blood was observed after 4 h (tmax) drug 
administration. Pharmacokinetics parameters of the drug “Argosil” 
in tissues and organs of mice are given in table 2, where 
AUC-area under the curve "concentration-time"; 
MRT-mean residence time of molecules of pharmacological agents in 
the body; 
fT–fraction of total amount of drug in the tissues-characterizes the 
intensity of penetration of pharmacological agents in the peripheral 
tissues
 
Table 2: Pharmacokinetic parameters of the drug “Argosil” in tissues and organs 
Organ AUC, (µg/g) min MRT Tissue fraction, fT 
minute hour 
Blood 3032 753 12.6 - 
Stomach 104240 444 7.4 34.38 
Lungs 17057 457 7.6 5.63 
Spleen 1267 783 13.1 0.49 
Liver 1204 766 12.8 0.40 
Kidneys 531 683 11.4 0.18 
Muscle 92 371 6.2 0.03 
After 4 h, the drug concentration in the blood gradually decreases and its accumulation observed in other internal organs (spleen, liver, kidney tmax = 8 h; Cmax 
= 14.22; 14.16; 7.60 µg/g, respectively). Only lungs are exceptions, in this organ the drug reaches maximum concentration after 4 h and Cmax is 29.85 µg/g. 
 
Analysis of muscle and skin tissues revealed no significant 
accumulation of silver in the course of the experiment. 
CONCLUSION 
It was shown maximum drug content observed in the stomach tissue 
at the intragastric administration. Accumulation and excretion of the 
drug “Argosil” from the tissue adequately approximated by the 
equation describing the model. Half-life of the drug was about 4 h at 
the initial stage. Taking into account the total content of the drug in all 
investigated organs and tissues, we may conclude rapid removal of the 
drug through the gastrointestinal tract. Accumulation of the drug in 
the internal organs have expressed time maximums (lungs-4 h, other 
organs-8 h). Maximum drug concentration observed also in the lung 
tissues. Lungs tissue fraction fT is 5.63, which substantially exceeds the 
value fT of other internal organs. In regards of this fact, and taken into 
account antiviral properties of this compound, “Argosil” can be more 
effective for lung infections treatment. The obtained results are an 
essential basis for further study of the mechanism of action of a new 
preparation and conduct of clinical trials. 
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